Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Gender neutral vaccination against HPV.

Powell N, Hibbitts S, Evans M.

BMJ. 2018 Sep 17;362:k3837. doi: 10.1136/bmj.k3837. No abstract available.

PMID:
30224424
2.

Human Papillomavirus DNA Methylation Predicts Response to Treatment Using Cidofovir and Imiquimod in Vulval Intraepithelial Neoplasia 3.

Jones SEF, Hibbitts S, Hurt CN, Bryant D, Fiander AN, Powell N, Tristram AJ.

Clin Cancer Res. 2017 Sep 15;23(18):5460-5468. doi: 10.1158/1078-0432.CCR-17-0040. Epub 2017 Jun 9.

3.

Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences.

Jelen MM, Chen Z, Kocjan BJ, Hošnjak L, Burt FJ, Chan PKS, Chouhy D, Combrinck CE, Estrade C, Fiander A, Garland SM, Giri AA, González JV, Gröning A, Hibbitts S, Luk TNM, Marinic K, Matsukura T, Neumann A, Oštrbenk A, Picconi MA, Sagadin M, Sahli R, Seedat RY, Seme K, Severini A, Sinchi JL, Smahelova J, Tabrizi SN, Tachezy R, Tohme Faybush S, Uloza V, Uloziene I, Wong YW, Židovec Lepej S, Burk RD, Poljak M.

J Virol. 2016 May 12;90(11):5503-5513. doi: 10.1128/JVI.03149-15. Print 2016 Jun 1.

4.

Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women.

Bryant D, Hibbitts S, Almonte M, Tristram A, Fiander A, Powell N.

J Clin Virol. 2015 May;66:66-71. doi: 10.1016/j.jcv.2015.03.001. Epub 2015 Mar 5.

PMID:
25866341
5.

Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.

Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A, Soldan K.

J Clin Pathol. 2015 Feb;68(2):135-40. doi: 10.1136/jclinpath-2014-202681. Epub 2014 Nov 19.

PMID:
25410654
6.

Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.

Tristram A, Hurt CN, Madden T, Powell N, Man S, Hibbitts S, Dutton P, Jones S, Nordin AJ, Naik R, Fiander A, Griffiths G.

Lancet Oncol. 2014 Nov;15(12):1361-8. doi: 10.1016/S1470-2045(14)70456-5. Epub 2014 Oct 7.

7.

Increased methylation of Human Papillomavirus type 16 DNA correlates with viral integration in Vulval Intraepithelial Neoplasia.

Bryant D, Onions T, Raybould R, Jones S, Tristram A, Hibbitts S, Fiander A, Powell N.

J Clin Virol. 2014 Nov;61(3):393-9. doi: 10.1016/j.jcv.2014.08.006. Epub 2014 Aug 15.

PMID:
25218242
8.

Evaluation of a commercially developed semiautomated PCR-surface-enhanced raman scattering assay for diagnosis of invasive fungal disease.

White PL, Hibbitts SJ, Perry MD, Green J, Stirling E, Woodford L, McNay G, Stevenson R, Barnes RA.

J Clin Microbiol. 2014 Oct;52(10):3536-43. doi: 10.1128/JCM.01135-14. Epub 2014 Jul 16.

9.

mRNA sequencing of novel cell lines from human papillomavirus type-16 related vulval intraepithelial neoplasia: consequences of expression of HPV16 E4 and E5.

Bryant D, Onions T, Raybould R, Flynn Á, Tristram A, Meyrick S, Giles P, Ashelford K, Hibbitts S, Fiander A, Powell N.

J Med Virol. 2014 Sep;86(9):1534-41. doi: 10.1002/jmv.23994. Epub 2014 Jun 5.

PMID:
24898764
10.

HPV integration detection in CaSki and SiHa using detection of integrated papillomavirus sequences and restriction-site PCR.

Raybould R, Fiander A, Wilkinson GW, Hibbitts S.

J Virol Methods. 2014 Sep;206:51-4. doi: 10.1016/j.jviromet.2014.05.017. Epub 2014 May 29.

PMID:
24880069
11.

Geographical distribution and risk association of human papillomavirus genotype 52-variant lineages.

Zhang C, Park JS, Grce M, Hibbitts S, Palefsky JM, Konno R, Smith-McCune KK, Giovannelli L, Chu TY, Picconi MA, Piña-Sánchez P, Settheetham-Ishida W, Coutlée F, De Marco F, Woo YL, Ho WC, Wong MC, Chirenje MZ, Magure T, Moscicki AB, Sabol I, Fiander AN, Chen Z, Chan MC, Cheung TH, Burk RD, Chan PK.

J Infect Dis. 2014 Nov 15;210(10):1600-4. doi: 10.1093/infdis/jiu310. Epub 2014 May 30.

12.

Global genomic diversity of human papillomavirus 6 based on 724 isolates and 190 complete genome sequences.

Jelen MM, Chen Z, Kocjan BJ, Burt FJ, Chan PK, Chouhy D, Combrinck CE, Coutlée F, Estrade C, Ferenczy A, Fiander A, Franco EL, Garland SM, Giri AA, González JV, Gröning A, Heidrich K, Hibbitts S, Hošnjak L, Luk TN, Marinic K, Matsukura T, Neumann A, Oštrbenk A, Picconi MA, Richardson H, Sagadin M, Sahli R, Seedat RY, Seme K, Severini A, Sinchi JL, Smahelova J, Tabrizi SN, Tachezy R, Tohme S, Uloza V, Vitkauskiene A, Wong YW, Zidovec Lepej S, Burk RD, Poljak M.

J Virol. 2014 Jul;88(13):7307-16. doi: 10.1128/JVI.00621-14. Epub 2014 Apr 16.

13.

Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: implications for tonsil cancer precursor lesions.

Palmer E, Newcombe RG, Green AC, Kelly C, Noel Gill O, Hall G, Fiander AN, Pirotte E, Hibbitts SJ, Homer J, Powell NG.

Int J Cancer. 2014 Nov 15;135(10):2437-43. doi: 10.1002/ijc.28886. Epub 2014 Apr 18.

14.

Does the HPV vaccination programme have implications for cervical screening programmes in the UK?

Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S.

Vaccine. 2014 Apr 1;32(16):1828-33. doi: 10.1016/j.vaccine.2014.01.087. Epub 2014 Feb 13.

15.

UK population based study to predict impact of HPV vaccination.

Hibbitts S, Tristram A, Beer H, McRea J, Rose B, Hauke A, Nuttall D, Dallimore N, Newcombe RG, Fiander A.

J Clin Virol. 2014 Feb;59(2):109-14. doi: 10.1016/j.jcv.2013.12.002. Epub 2013 Dec 12.

PMID:
24388208
16.

Quantitative measurement of Human Papillomavirus type 16 L1/L2 DNA methylation correlates with cervical disease grade.

Bryant D, Tristram A, Liloglou T, Hibbitts S, Fiander A, Powell N.

J Clin Virol. 2014 Jan;59(1):24-9. doi: 10.1016/j.jcv.2013.10.029. Epub 2013 Nov 4.

PMID:
24268385
17.

Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK).

Powell N, Cuschieri K, Cubie H, Hibbitts S, Rosillon D, De Souza SC, Molijn A, Quint W, Holl K, Fiander A.

J Clin Virol. 2013 Nov;58(3):571-4. doi: 10.1016/j.jcv.2013.08.020. Epub 2013 Aug 30.

PMID:
24051043
18.

Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England.

Bowyer HL, Marlow LA, Hibbitts S, Pollock KG, Waller J.

Vaccine. 2013 Feb 4;31(7):1051-6. doi: 10.1016/j.vaccine.2012.12.038. Epub 2012 Dec 28.

PMID:
23277094
19.

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

Chan PK, Zhang C, Park JS, Smith-McCune KK, Palefsky JM, Giovannelli L, Coutlée F, Hibbitts S, Konno R, Settheetham-Ishida W, Chu TY, Ferrera A, Alejandra Picconi M, De Marco F, Woo YL, Raiol T, Piña-Sánchez P, Bae JH, Wong MC, Chirenje MZ, Magure T, Moscicki AB, Fiander AN, Capra G, Young Ki E, Tan Y, Chen Z, Burk RD, Chan MC, Cheung TH, Pim D, Banks L.

Int J Cancer. 2013 Jun 1;132(11):2528-36. doi: 10.1002/ijc.27932. Epub 2012 Nov 29.

20.

Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection.

Jones J, Saleem A, Rai N, Shylasree TS, Ashman S, Gregory K, Powell N, Tristram A, Fiander A, Hibbitts S.

J Clin Virol. 2011 Oct;52(2):88-92. doi: 10.1016/j.jcv.2011.06.021. Epub 2011 Aug 9.

PMID:
21831706
21.

Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA Microarray.

Bryant D, Rai N, Rowlands G, Hibbitts S, Jones J, Tristram A, Fiander A, Powell N.

J Med Virol. 2011 Aug;83(8):1358-61. doi: 10.1002/jmv.22107. Epub 2011 May 26.

PMID:
21618551
22.

Identification of human papillomavirus type 58 lineages and the distribution worldwide.

Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, Giovannelli L, Coutlée F, Hibbitts S, Chu TY, Settheetham-Ishida W, Picconi MA, Ferrera A, De Marco F, Woo YL, Raiol T, Piña-Sánchez P, Cheung JL, Bae JH, Chirenje MZ, Magure T, Moscicki AB, Fiander AN, Di Stefano R, Cheung TH, Yu MM, Tsui SK, Pim D, Banks L.

J Infect Dis. 2011 Jun 1;203(11):1565-73. doi: 10.1093/infdis/jir157.

23.

Development of optimal liquid based cytology sample processing methods for HPV testing: minimising the 'inadequate' test result.

Peevor R, Jones J, Fiander AN, Hibbitts S.

J Virol Methods. 2011 May;173(2):374-7. doi: 10.1016/j.jviromet.2011.01.020. Epub 2011 Feb 3.

PMID:
21295606
25.

The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population.

Powell NG, Hibbitts SJ, Boyde AM, Newcombe RG, Tristram AJ, Fiander AN.

Int J Cancer. 2011 Apr 1;128(7):1676-82. doi: 10.1002/ijc.25485. Epub 2010 May 25.

26.

Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?

Saleem A, Tristram A, Fiander A, Hibbitts S.

Minerva Med. 2009 Dec;100(6):503-23. Review.

PMID:
20010484
27.

Should boys receive the human papillomavirus vaccine? Yes.

Hibbitts S.

BMJ. 2009 Dec 7;339:b4928. doi: 10.1136/bmj.b4928. No abstract available.

PMID:
19969602
28.
29.

Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.

Jones J, Powell NG, Tristram A, Fiander AN, Hibbitts S.

J Clin Virol. 2009 Jun;45(2):100-4. doi: 10.1016/j.jcv.2009.02.013. Epub 2009 Apr 24.

PMID:
19394266
30.

Human Papillomavirus negative but dyskaryotic cervical cytology: re-analysis of molecular testing.

Peevor R, Bowden S, Jones J, Fiander AN, Hibbitts S.

J Clin Virol. 2009 Apr;44(4):322-4. doi: 10.1016/j.jcv.2009.01.015. Epub 2009 Mar 4.

PMID:
19264544
31.

Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study.

Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN.

Br J Cancer. 2008 Dec 2;99(11):1929-33. doi: 10.1038/sj.bjc.6604748. Epub 2008 Oct 28.

32.

Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.

Slingluff CL Jr, Yamshchikov GV, Hogan KT, Hibbitts SC, Petroni GR, Bissonette EA, Patterson JW, Neese PY, Grosh WW, Chianese-Bullock KA, Czarkowski A, Rehm PK, Parekh J.

Ann Surg Oncol. 2008 Dec;15(12):3538-49. doi: 10.1245/s10434-008-0046-4. Epub 2008 Oct 16.

33.

Human papillomavirus infection in Barrett's oesophagus in the UK: an infrequent event.

Rai N, Jenkins GJ, McAdam E, Hibbitts SJ, Fiander AN, Powell NG.

J Clin Virol. 2008 Oct;43(2):250-2. doi: 10.1016/j.jcv.2008.07.004. Epub 2008 Aug 21.

PMID:
18718811
34.

The role of respiratory viruses in cystic fibrosis.

Wat D, Gelder C, Hibbitts S, Cafferty F, Bowler I, Pierrepoint M, Evans R, Doull I.

J Cyst Fibros. 2008 Jul;7(4):320-8. doi: 10.1016/j.jcf.2007.12.002. Epub 2008 Feb 6.

35.

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK.

Clin Cancer Res. 2007 Nov 1;13(21):6386-95.

36.

Is there a role for influenza vaccination in cystic fibrosis?

Wat D, Gelder C, Hibbitts S, Bowler I, Pierrepoint M, Evans R, Doull I.

J Cyst Fibros. 2008 Jan;7(1):85-8. Epub 2007 Jul 5.

37.

Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia.

Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, Tristram AJ, Beukenholdt RW, Powell NG.

J Med Virol. 2007 Sep;79(9):1366-9.

PMID:
17607770
38.

Human papillomavirus infection: an anonymous prevalence study in South Wales, UK.

Hibbitts S, Rieck GC, Hart K, Powell NG, Beukenholdt R, Dallimore N, McRea J, Hauke A, Tristram A, Fiander AN.

Br J Cancer. 2006 Jul 17;95(2):226-32. Epub 2006 Jul 4.

39.

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.

Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL Jr.

J Immunol. 2005 Mar 1;174(5):3080-6.

40.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P.

J Clin Oncol. 2004 Nov 15;22(22):4474-85.

PMID:
15542798
41.

Competition among peptides in melanoma vaccines for binding to MHC molecules.

Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, Deacon DH, Engelhard VH, Slingluff CL Jr.

J Immunother. 2004 Nov-Dec;27(6):425-31.

PMID:
15534486
42.

Development and evaluation of a real-time nucleic acid sequence based amplification assay for rapid detection of influenza A.

Moore C, Hibbitts S, Owen N, Corden SA, Harrison G, Fox J, Gelder C, Westmoreland D.

J Med Virol. 2004 Dec;74(4):619-28.

PMID:
15484279
44.

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH.

J Clin Oncol. 2003 Nov 1;21(21):4016-26.

PMID:
14581425
45.

Development and evaluation of NucliSens basic kit NASBA for diagnosis of parainfluenza virus infection with 'end-point' and 'real-time' detection.

Hibbitts S, Rahman A, John R, Westmoreland D, Fox JD.

J Virol Methods. 2003 Mar;108(2):145-55.

PMID:
12609681
46.

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG.

Clin Cancer Res. 2001 Oct;7(10):3012-24.

47.

Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands.

Simmons G, Reeves JD, Hibbitts S, Stine JT, Gray PW, Proudfoot AE, Clapham PR.

Immunol Rev. 2000 Oct;177:112-26. Review.

PMID:
11138769
48.

Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1.

Hibbitts S, Reeves JD, Simmons G, Gray PW, Epstein LG, Schols D, de Clercq E, Wells TN, Proudfoot AE, Clapham PR.

AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):989-1000.

PMID:
10445811
49.
50.

HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands.

Clapham PR, Reeves JD, Simmons G, Dejucq N, Hibbitts S, McKnight A.

Mol Membr Biol. 1999 Jan-Mar;16(1):49-55. Review.

PMID:
10332737

Supplemental Content

Loading ...
Support Center